Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732276 | 0.87 | FABP4 (0.41) | TDP1LMNAHTTMAPTPGR | |
| SCHEMBL5710694 | 0.86 | FFAR1 (0.46) | TDP1LMNAHTTMAPTPGR | |
| SCHEMBL5731410 | 0.85 | SRD5A2 (0.46) | TDP1LMNAHTTMAPTPGR | |
| SCHEMBL5710686 | 0.84 | TRAP1 (0.51) | TDP1LMNAHTTMAPTPGR | |
| SCHEMBL5731392 | 0.83 | MAPK1 (0.47) | TDP1LMNAHTTMAPTPGR | |
| SCHEMBL5731060 | 0.81 | ALDH1A1 (0.45) | TDP1LMNAHTTMAPTIDO1 | |
| SCHEMBL13675411 | 0.81 | LMNA (0.57) | TDP1LMNAHTTMAPTCYP2C9 | |
| SCHEMBL5732481 | 0.80 | APEX1 (0.52) | MAPK1AKR1B1FFAR1KDM4EPTGER4 | |
| SCHEMBL5732483 | 0.80 | APEX1 (0.52) | MAPK1AKR1B1FFAR1KDM4EPTGER4 | |
| SCHEMBL5731614 | 0.79 | HPGD (0.49) | LMNAMAPTPOLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | claimed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | claimed |
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-6943196-B1 | NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-09-13 | — | — | US | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | NFKBIA, NFKB2, NFKB1 | TDP1 2008/4885LMNA 79/4885HTT 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.